Related Experiment Videos
[Coronary angioplasty with the implantation of a vascular support (stent)]
U Tebbe1, R A Schatz, K H Scholz
1Abteilung Kardiologie und Pulmonologie, Zentrum Innere Medizin der Universität Göttingen.
Insights
This study highlights the successful use of a Palmaz-Schatz stent following percutaneous transluminal coronary angioplasty (PTCA) to treat severe restenosis in coronary heart disease. The intervention prevented further narrowing, improving patient outcomes.
Area of Science:
- Interventional Cardiology
- Cardiovascular Medicine
- Medical Device Technology
Background:
- Coronary heart disease (CHD) presents significant challenges, often involving angina and arterial stenosis.
- Percutaneous transluminal coronary angioplasty (PTCA) is a common treatment for coronary artery stenosis, but restenosis remains a concern.
- Recurrent stenosis after initial PTCA necessitates advanced therapeutic strategies.
Abstract:
Coronary angiography in a 55-year-old man with coronary heart disease and typical physical activity-induced angina revealed a subtotal stenosis in the middle third of the right coronary artery while left ventricular function was normal. Percutaneous transluminal coronary angioplasty (PTCA) was performed in January 1989, achieving a residual stenosis of less than 50%. However, restenosis of more than 90% developed within six months, necessitating another PTCA, followed immediately by implantation of a metal (Palmaz-Schatz) stent in the stenotic area. No stenosis was demonstrable afterwards. Maintenance medication with anticoagulants (phenprocoumon) and platelet-function inhibitors (aspirin and dipyridamole) was instituted and repeat angiography three months later demonstrated good dilatation results without any restenosis.